Abstract: A method for identifying and treating membranous nephropathy (MN) includes identifying the patient as in need of treatment by having an assay carried out. The assay includes contacting a sample from the patient with a PLA2R epitope bound to a label, and identifying an increase in the amount of binding of the labeled PLA2R epitope in the sample relative to the amount of binding expected in a control sample, thereby identifying the patient as needing treatment for MN. The identified patient can be treated by administering an agent that reduces or eliminates the anti-PLA2R autoantibody-producing B cell population.

Abstract: Human leukocyte antigen (HLA) coated magnetic bead compositions, panels and methods of use thereof. A method of isolating HLA-specific antibodies including: contacting the composition of the disclosure with a liquid sample to specifically bind antibodies present in the liquid sample to HLA immobilized on magnetic beads; separating magnetic beads having antibodies bound to HLA of the magnetic beads from the liquid sample; and isolating the bound antibodies.

Abstract: Compositions, methods, and kits are for the diagnosis, prevention and/or treatment of autoimmune diseases by detecting, targeting, and/or eliminating epitope-specific autoimmune cells. The compositions include a conjugate of an epitope and an agent that allows for detecting, targeting, and/or eliminating epitope-specific autoimmune cells.

Abstract: Compositions, methods, and kits are for the diagnosis, prevention and/or treatment of autoimmune diseases by detecting, targeting, and/or eliminating epitope-specific autoimmune cells. The compositions include a conjugate of an epitope and an agent that allows for detecting, targeting, and/or eliminating epitope-specific autoimmune cells.

Abstract: Compositions, methods, and kits are for the diagnosis, prevention and/or treatment of autoimmune diseases by detecting, targeting, and/or eliminating epitope-specific autoimmune cells. The compositions include a conjugate of an epitope and an agent that allows for detecting, targeting, and/or eliminating epitope-specific autoimmune cells.

Abstract: Disclosed is a halogen-free high-frequency resin composition calculated according to parts by weight, and including 20-50 parts by weight of dicyclopentadiene epoxy resin, 10-40 parts by weight of styrene-maleic anhydride copolymer, 10-30 parts by weight of benzoxazine resin, 5-20 parts by weight of polyfunctional epoxy resin and 20-40 parts by weight of at least one phosphorus-containing flame retardant. A copper clad laminate made of the halogen-free high-frequency resin composition has excellent properties including a low dielectric constant, a low dielectric loss, a high heat resistance, a low water absorption, a low coefficient of expansion and a high PCB manufacturability.

Abstract: Disclosed is a halogen-free low-expansion resin composition including a polyfunctional epoxy resin, a phosphorus-containing epoxy resin, a benzoxazine resin, a phosphorus-containing curing agent, an inorganic filler, a curing accelerator, and a solvent. The rigid and firm resins and inorganic filler contained in the composition provide a low coefficient of thermal expansion and a high heat resistance, so that laminates made of this composition are applicable for IC packaging substrates, and the laminates contain halogen-free compounds with a flame retardant rating of UL94-V0 grade.

Abstract: Disclosed is a halogen-free epoxy resin composition for integrated circuit packaging, and the resin composition includes a polyfunctional epoxy resin, a benzoxazine resin, a phosphorus-containing a curing agent, an inorganic filler, a curing accelerator and a solvent. The rigid and firm resins and inorganic filler contained in the composition provide a low coefficient of thermal expansion and a high heat resistance, so that laminates made of this composition are applicable for IC packaging substrates, and the laminates contain halogen-free compounds with a flame retardant rating of UL94-V0 grade.